Platelet-type von willebrand disease: New insights into the molecular pathophysiology of a unique platelet defect

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 6, 2013, Pages 663-673

  Othman, Maha ^a,b   Kaur, Harmanpreet ^a   Emsley, Jonas ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b St Lawrence College Kingston   (Canada)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

crystal structure of GPIb VWF complex; gain of function mutations; GPIb ; platelet functional defects; platelet glycoproteins

Indexed keywords

RISTOCETIN; THROMBIN RECEPTOR; VON WILLEBRAND FACTOR;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BLOOD CLOTTING FACTOR DEFICIENCY; DELETION MUTANT; GAIN OF FUNCTION MUTATION; HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR PATHOLOGY; PHENOTYPE; PLATELET TYPE VON WILLEBRAND DISEASE; PREGNANCY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA;

BLOOD PLATELETS; HEMORRHAGE; HEMOSTASIS; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; PLATELET AGGREGATION; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84883251909     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1353442     Document Type: Article

References (92)

1. Peyvandi F., Palla R., Menegatti M., Mannucci P. M. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost: 2009; 35 4 349 355
2. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost: 2003; 1 7 1628 1636
3. Weiss H. J. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol: 1994; 31 4 312 319
4. Ruggeri Z. M. The role of von Willebrand factor in thrombus formation. Thromb Res: 2007; 120 01 S5 S9
5. Suva L. J., Hartman E., Dilley J. D., et al. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol: 2008; 172 2 430 439
6. Ware J. Dysfunctional platelet membrane receptors: from humans to mice. Thromb Haemost: 2004; 92 3 478 485
7. Ware J., Russell S. R., Marchese P., Ruggeri Z. M. Expression of human platelet glycoprotein Ib alpha in transgenic mice. J Biol Chem: 1993; 268 11 8376 8382
8. Guerrero J. A., Kyei M., Russell S., et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood: 2009; 114 27 5541 5546
9. Othman M. Differential identification of PT-VWD from type 2B VWD and GP1BA nomenclature issues. Br J Haematol: 2008; 142 2 312 314, author reply 314-315
10. Facey D. A., Favaloro E. J., Koutts J., Berndt M. C., Hertzberg M. S. Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease. Br J Haematol: 1999; 105 2 538 541
11. Favaloro E. J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost: 2008; 34 1 113 127
12. Favaloro E. J. 2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. Br J Haematol: 2006; 135 1 141 142, author reply 143
13. Favaloro E. J., Bonar R., Meiring M., Street A., Marsden K.; RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost: 2007; 98 2 346 358
14. Favaloro E. J., Koutts J. 2B or not 2B? Masquerading as von Willebrand disease? J Thromb Haemost: 2012; 10 2 317 319
15. Favaloro E. J., Patterson D., Denholm A., et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet- agglutination mixing assay and confirmed by genetic analysis. Br J Haematol: 2007; 139 4 623 626
16. Hamilton A., Ozelo M., Leggo J., et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost: 2011; 105 3 501 508
17. Othman M., Favaloro E. J. Genetics of type 2B von Willebrand disease: "true 2B,o" "tricky 2B,o" or "not 2B.o" What are the modifiers of the phenotype? Semin Thromb Hemost: 2008; 34 6 520 531
18. Miller J. L. Platelet-type von Willebrand disease. Thromb Haemost: 1996; 75 6 865 869
19. Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev: 2011; 25 4 147 153
20. Weiss H. J., Meyer D., Rabinowitz R., et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med: 1982; 306 6 326 333
21. Miller J. L., Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood: 1982; 60 3 790 794
22. Takahashi H., Nagayama R., Hattori A., Ihzumi T., Tsukada T., Shibata A. Von Willebrand disease associated with familial thrombocytopenia and increased ristocetin-induced platelet aggregation. Am J Hematol: 1981; 10 1 89 99
23. Takahashi H., Sakuragawa N., Shibata A. Von Willebrand disease with an increased ristocetin-induced platelet aggregation and a qualitative abnormality of the factor VIII protein. Am J Hematol: 1980; 8 3 299 308
24. Enayat M. S., Guilliatt A. M., Lester W., Wilde J. T., Williams M. D., Hill F. G. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol: 2006; 133 6 664 666
25. Giannini S., Cecchetti L., Mezzasoma A. M., Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica: 2010; 95 6 1021 1024
26. Franchini M., Montagnana M., Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol: 2008; 30 2 91 94
27. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost: 2003; 29 2 125 130
28. Stirling Y., Woolf L., North W. R., Seghatchian M. J., Meade T. W. Haemostasis in normal pregnancy. Thromb Haemost: 1984; 52 2 176 182
29. Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost: 1998; 79 6 1166 1170
30. Brenner B. Haemostatic changes in pregnancy. Thromb Res: 2004; 114 5-6 409 414
31. Bonnar J. Hemostatic function and coagulopathy during pregnancy. Obstet Gynecol Annu: 1978; 7 195 217
32. Coopland A. AN, Alkjaersig N., Fletcher A. P. Reduction in plasma factor 13 (fibrin stabilizing factor) concentration during pregnancy. J Lab Clin Med: 1969; 73 1 144 153
33. O'Brien W. F., Saba H. I., Knuppel R. A., Scerbo J. C., Cohen G. R. Alterations in platelet concentration and aggregation in normal pregnancy and preeclampsia. Am J Obstet Gynecol: 1986; 155 3 486 490
34. Holthe M. R., Staff A. C., Berge L. N., Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol: 2004; 190 4 1128 1134
35. Noller K. L., Bowie E. J., Kempers R. D., Owen C. A. Jr. Von Willebrand's disease in pregnancy. Obstet Gynecol: 1973; 41 6 865 872
36. Othman M., Notley C., Lavender F. L., et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood: 2005; 105 11 4330 4336
37. Grover N., Boama V., Chou M. R. Pseudo (platelet-type) von Willebrand disease in pregnancy: a case report. BMC Pregnancy Childbirth: 2013; 13 16
38. O'Connor D., Lester W., Willoughby S., Wilde J. T. Pregnancy in platelet-type VWD: a case series. Thromb Haemost: 2011; 106 2 386 387
39. Reininger A. J., Heijnen H. F., Schumann H., Specht H. M., Schramm W., Ruggeri Z. M. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood: 2006; 107 9 3537 3545
40. Andrews R. K., Gardiner E. E., Shen Y., Berndt M. C. Structure-activity relationships of snake toxins targeting platelet receptors, glycoprotein Ib-IX-V and glycoprotein VI. Curr Med Chem Cardiovasc Hematol Agents: 2003; 1 2 143 149
41. Li R., Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost: 2013; 11 4 605 614
42. Gawaz M., Langer H., May A. E. Platelets in inflammation and atherogenesis. J Clin Invest: 2005; 115 12 3378 3384
43. Romo G. M., Dong J. F., Schade A. J., et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med: 1999; 190 6 803 814
44. Simon D. I., Chen Z., Xu H., et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med: 2000; 192 2 193 204
45. Andrews R. K., López J. A., Berndt M. C. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol: 1997; 29 1 91 105
46. Wang Y., Sakuma M., Chen Z., et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation: 2005; 112 19 2993 3000
47. Langer H. F., Daub K., Braun G., et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol: 2007; 27 6 1463 1470
48. Weeterings C., de Groot P. G., Adelmeijer J., Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood: 2008; 112 8 3227 3233
49. Lisman T., de Groot P. G. The interaction of recombinant factor VIIa with platelet glycoprotein Ib. Thromb Res: 2010; 125 01 S13 S15
50. Baglia F. A., Badellino K. O., Li C. Q., Lopez J. A., Walsh P. N. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem: 2002; 277 3 1662 1668
51. Joseph K., Nakazawa Y., Bahou W. F., Ghebrehiwet B., Kaplan A. P. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med: 1999; 5 8 555 563
52. Bradford H. N., Pixley R. A., Colman R. W. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem: 2000; 275 30 22756 22763
53. Baglia F. A., Gailani D., López J. A., Walsh P. N. Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. J Biol Chem: 2004; 279 44 45470 45476
54. Baglia F. A., Shrimpton C. N., Emsley J., et al. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem: 2004; 279 47 49323 49329
55. Celikel R., McClintock R. A., Roberts J. R., et al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science: 2003; 301 5630 218 221
56. Dumas J. J., Kumar R., Seehra J., Somers W. S., Mosyak L. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. Science: 2003; 301 5630 222 226
57. Adam F., Guillin M. C., Jandrot-Perrus M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem: 2003; 270 14 2959 2970
58. Andrew R. K., Berndt M. C. Bernard-Soulier syndrome: an update. Semin Thromb Hemost: 2013;; DOI: 10.1055/s-0033-1353390
59. Cauwenberghs N., Meiring M., Vauterin S., et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol: 2000; 20 5 1347 1353
60. Cauwenberghs N., Vanhoorelbeke K., Vauterin S., et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood: 2001; 98 3 652 660
61. Fontayne A., Vanhoorelbeke K., Pareyn I., et al. Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost: 2006; 96 5 671 684
62. Wu D., Meiring M., Kotze H. F., Deckmyn H., Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol: 2002; 22 2 323 328
63. Wu D., Vanhoorelbeke K., Cauwenberghs N., et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood: 2002; 99 10 3623 3628
64. Hennan J. K., Swillo R. E., Morgan G. A., et al. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost: 2006; 95 3 469 475
65. Benard S. A., Smith T. M., Cunningham K., et al. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry: 2008; 47 16 4674 4682
66. Miller J. L., Cunningham D., Lyle V. A., Finch C. N. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A: 1991; 88 11 4761 4765
67. Russell S. D., Roth G. J. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood: 1993; 81 7 1787 1791
68. Kunishima S., Heaton D. C., Naoe T., et al. De novo mutation of the platelet glycoprotein Ib alpha gene in a patient with pseudo-von Willebrand disease. Blood Coagul Fibrinolysis: 1997; 8 5 311 315
69. Murata M., Russell S. R., Ruggeri Z. M., Ware J. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest: 1993; 91 5 2133 2137
70. Moriki T., Murata M., Kitaguchi T., et al. Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239 -> Val) reported in patients with platelet-type von Willebrand disease. Blood: 1997; 90 2 698 705
71. Matsubara Y., Murata M., Sugita K., Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost: 2003; 1 10 2198 2205
72. Nurden P., Lanza F., Bonnafous-Faurie C., Nurden A. A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene. Thromb Haemost: 2007; 97 2 319 321
73. Enayat S., Ravanbod S., Rassoulzadegan M., et al. A novel D235Y mutation in the GP1BA gene enhances platelet interaction with von Willebrand factor in an Iranian family with platelet-type von Willebrand disease. Thromb Haemost: 2012; 108 5 946 954
74. Uff S., Clemetson J. M., Harrison T., Clemetson K. J., Emsley J. Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem: 2002; 277 38 35657 35663
75. Dumas J. J., Kumar R., McDonagh T., et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem: 2004; 279 22 23327 23334
76. Huizinga E. G., Tsuji S., Romijn R. A., et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science: 2002; 297 5584 1176 1179
77. Dong J., Schade A. J., Romo G. M., et al. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem: 2000; 275 36 27663 27670
78. Fukuda K., Doggett T., Laurenzi I. J., Liddington R. C., Diacovo T. G. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol: 2005; 12 2 152 159
79. Laskowski R. A. PDBsum new things. Nucleic Acids Res: 2009; 37 (Database issue): D355 D359
80. McEwan P. A., Andrews R. K., Emsley J. Glycoprotein Ibalpha inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood: 2009; 114 23 4883 4885
81. McEwan P. A., Yang W., Carr K. H., et al. Quaternary organization of GPIb-IX complex and insights into Bernard-Soulier syndrome revealed by the structures of GPIbβ and a GPIbβ/GPIX chimera. Blood: 2011; 118 19 5292 5301
82. Ware J., Russell S. R., Marchese P., et al. Point mutation in a leucine-rich repeat of platelet glycoprotein Ib alpha resulting in the Bernard-Soulier syndrome. J Clin Invest: 1993; 92 3 1213 1220
83. Nowak A. A., Canis K., Riddell A., Laffan M. A., McKinnon T. A. O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood: 2012; 120 1 214 222
84. Auton M., Sowa K. E., Behymer M., Cruz M. A. N-terminal flanking region of A1 domain in von Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under shear stress. J Biol Chem: 2012; 287 18 14579 14585
85. Law R. H., Caradoc-Davies T., Cowieson N., et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep: 2012; 1 3 185 190
86. Bowman M., Mundell G., Grabell J., et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost: 2008; 6 12 2062 2066
87. Kaur H., McEacern K., James P., Othman M. International systematic study for assessment of bleeding phenotype in platelet type von Willebrand disease. Paper presented at: 26th Congress of the International Society on Thrombosis and Haemostasis; June 29-July 4, 2013; Amsterdam, The Netherlands
88. Cranmer S. L., Pikovski I., Mangin P., et al. Identification of a unique filamin A binding region within the cytoplasmic domain of glycoprotein Ibalpha. Biochem J: 2005; 387 Pt 3 849 858
89. Shimizu A., Matsushita T., Kondo T., et al. Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis. J Biol Chem: 2004; 279 16 16285 16294
90. De Cristofaro R., De Candia E., Rutella S., Weitz J. I. The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. J Biol Chem: 2000; 275 6 3887 3895
91. De Marco L., Mazzucato M., Masotti A., Ruggeri Z. M. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem: 1994; 269 9 6478 6484
92. Ward C. M., Andrews R. K., Smith A. I., Berndt M. C. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ib alpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry: 1996; 35 15 4929 4938